Levetiracetam

Levetiracetam is used to treat partial epilepsies, tonic-clonic epilepsy and juvenile myoclonic epilepsy, per the National Library of Medicine's MED-RT classification. The brand product was first FDA-approved on Nov 30, 1999, and the first generic was approved Nov 4, 2008. FDA's Orange Book lists 94 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $255 million on Levetiracetam across 4.9 million claims for 849,000 beneficiaries.

Levetiracetam is available as 155 NDCs from 33 manufacturers (144 generic, 11 brand), with NADAC prices from $0.05 to $19.87 per EA — the most expensive product costs about 402× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.